Peptide Helix-Y12as Potential Effector for Peroxisome Proliferator-Activated Receptors


Por: Carrillo-Tripp M., Reyes Y., Delgado-Coello B., Mas-Oliva J., Gutiérrez-Vidal R.

Publicada: 1 ene 2023
Resumen:
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in the regulation of lipids and glucose metabolism, and immune response. Therefore, they have been considered pharmacological targets for treating metabolic diseases, such as dyslipidemia, atherosclerosis, and non-alcoholic fatty liver disease. However, the available synthetic ligands of PPARs have mild to significant side effects, generating the necessity to identify new molecules that are selective PPAR ligands with specific biological responses. This study aimed to evaluate some components of the atheroprotective and hepatoprotective HB-ATV-8 nanoparticles [the amphipathic peptide Helix-Y12, thermozeaxanthin, thermozeaxanthin-13, thermozeaxanthin-15, and a set of glycolipids], as possible ligands of PPARs through blind molecular docking. According to the change in free energy upon protein-ligand binding, Gb, thermozeaxanthins show a more favorable interaction with PPARs, followed by Helix-Y12. Moreover, Helix-Y12 interacts with most parts of the Y-shaped ligand-binding domain (LBD), surrounding helix 3 of PPARs, and reaching helix 12 of PPARa and PPAR?. As previously reported for other ligands, Tyr314 and Tyr464 of PPARa interact with Helix-Y12 through hydrogen bonds. Several PPARa's amino acids are involved in the ligand binding by hydrophobic interactions. Furthermore, we identified additional PPARs' amino acids interacting with Helix-Y12 through hydrogen bonds still not reported for known ligands. Our results show that, from the studied ligand set, the Helix-Y12 peptide and Tzeaxs have the most significant probability of binding to the PPARs' LBD, suggesting novel ligands for PPARs. © 2023 Mauricio Carrillo-Tripp et al.

Filiaciones:
Carrillo-Tripp M.:
 Biomolecular Diversity Laboratory, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Unidad Monterrey, Vía del Conocimiento 201, PIIT, Nuevo León, Apodaca, C.P. 66600, Mexico

Reyes Y.:
 Metabolic Diseases Laboratory, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Unidad Monterrey, Vía del Conocimiento 201, PIIT, Nuevo León, Apodaca, C.P. 66600, Mexico

 Universidad Politécnica de Puebla, Tercer Carril del Ejido, Serrano s/n, Cuanalá, Puebla, C.P. 7264, Mexico

Delgado-Coello B.:
 Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, CDMX, C.P. 04510, Mexico

Mas-Oliva J.:
 Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, CDMX, C.P. 04510, Mexico

Gutiérrez-Vidal R.:
 Metabolic Diseases Laboratory, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Unidad Monterrey, Vía del Conocimiento 201, PIIT, Nuevo León, Apodaca, C.P. 66600, Mexico

 Programa de Investigadoras e Investigadores Por México, Conacyt, CDMX, Mexico
ISSN: 16874757
Editorial
HINDAWI PUBLISHING CORPORATION, 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 2023 Número:
Páginas:
WOS Id: 000972951500001
ID de PubMed: 37096195
imagen gold, Gold